The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The efficacy of oxaliplatin (Ox) when added to 5-fluorouracil/leucovorin (FU/L) in stage II colon cancer.
G. A. Yothers
No relevant relationships to disclose
C. J. Allegra
No relevant relationships to disclose
M. J. O'Connell
Consultant or Advisory Role - Sanofi
T. J. George
No relevant relationships to disclose
S. Sharif
No relevant relationships to disclose
N. J. Petrelli
Consultant or Advisory Role - Genentech
S. Lopa
No relevant relationships to disclose
N. Wolmark
Consultant or Advisory Role - Roche/Genentech (U)